texas oncology more breakthroughs. more victories
  • Request an Appointment
  • Find a cancer center
  • Find a provider
  • Clinical Trials

Share:

 
 

Nathan Shumway, D.O., FACP

General Summary

Dr. Nathan Shumway specializes in medical oncology and hematology.

While in the Army, Dr. Shumway served as the Training Program Director for the largest Hematology and Medical Oncology Fellowship in the Department of Defense. While on staff at SAUSHEC, he received formal training in communication skills through the Oncotalk Teach® Course, and is an Adjunct Clinical Assistant Professor of Medicine for the University of Texas Health Science Center in San Antonio.

While on active duty, Dr. Shumway served as the Principle Investigator for six breast cancer vaccine trials and has numerous peer reviewed publications and abstracts focusing in the areas of medical education, breast cancer and benign hematology and has presented his research at the local, regional and national level.

Dr. Shumway was deployed in support of Operation Iraqi Freedom and Operation New Dawn in 2010. During this time he served as Chief of Inpatient Medicine for the 21st Combat Support Hospital and was appointed Theater Hematology/Oncology Consultant for the Iraqi Joint Operations Area. Prior to departure from the military, he reached the rank of Lieutenant Colonel, and gained valuable practice experience treating numerous patients with a variety of cancer and blood disorders.

Education

  • Fellowship
    Hematology and Medical Oncology, San Antonio Uniformed Services Health Education Consortium, Brooke Army Medical Center, San Antonio, TX
  • Residency
    Internal Medicine, Walter Reed Army Medical Center, Washington, D.C.
  • Internship
    Walter Reed Army Medical Center, Washington, D.C.
  • Medical Doctorate
    Western University of Health Sciences, College of Osteopathic Medicine of the Pacific, Pomona, CA

Medical Practice

Other Information

Dr. Shumway is married to Judy Shumway, D.O., M.P.H., a hospitalist in San Antonio. They have 2 sons.

Accolades & Memberships

Community Service

Research Interest

Publications

  • Peripheral Smear Review and Bone Marrow Biopsy Correlation

    Journal of Clinical and Diagnostic Research, 2017

  • Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis.

    Support Care Cancer, 2016

  • Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence.

    Annals of Oncology, 2016

  • Correlation Between Preexisting Immunity and Clinical Response in a Phase II Trial Using HER2-Based Peptide Vaccines to Prevent Breast Cancer Recurrence

    Annals of Surgical Oncology, 2016

  • Efficacy of Booster Inoculations in a Phase II Trial of GP2, a HER2-Derived Peptide Vaccine, for the Prevention of Breast Cancer Recurrence

    Annals of Surgical Oncology, 2016

Show all Publications
  • Impact of Boosting in the Phase II Trial of the AE37+ GM-CSF Vaccine in High-risk Breast Cancer Patients to Prevent Recurrence

    Annals of Surgical Oncology, 2016

  • Use of milestones and development of entrustable professional activities in 2 hematology/oncology training programs

    Journal of Graduate Medical Education, 2015

  • A randomized pilot study comparing olanzapine (Zyprexa) to aprepitant (Emend) for treatment of chemotherapy-induced nausea and vomiting

    Journal of Pain Management, 2015

  • Correlation of peripheral blood smear review and bone marrow biopsies for benign hematology Outpatient referrals.

    ASCO Annual Meeting Proceedings, 2015

  • Final pre-specified analysis of the phase II trial of the AE37+ GM-CSF vaccine in high risk breast cancer patients to prevent recurrence.

    ASCO Annual Meeting Proceedings, 2015

  • Peripheral Blood Smear Utilization within a Military Hematology/Oncology Fellowship Program

    Blood, 2014

  • Informed consent training for medical oncology fellows: Checklist-based simulation exercise.

    ASCO Annual Meeting Proceedings, 2014

  • Chemotherapy infusion reaction training for medical oncology fellows: A checklist-based simulation exercise.

    ASCO Annual Meeting Proceedings, 2014

  • Current approaches and challenges in monitoring treatment responses in breast cancer

    Journal of Cancer, 2014

  • Current approaches and challenges in early detection of breast cancer recurrence

    Journal of Cancer, 2014

  • Future directions for monitoring treatment responses in breast cancer

    Journal of Cancer, 2014

  • Future directions for the early detection of recurrent breast cancer

    Journal of Cancer, 2014

  • Primary analysis of the prospective, randomized, phase II trial of GP2+ GM-CSF vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients

    ASCO Annual Meeting Proceedings, 2014

  • Comparison of recurrent and nonrecurrent breast cancer patients undergoing AE37 peptide vaccine therapy.

    ASCO Annual Meeting Proceedings, 2014

  • Primary analysis of the prospective, randomized, single-blinded phase II trial of AE37 vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients.

    ASCO Annual Meeting Proceedings, 2014

  • Use Of Milestones And Development Of Entrustable Professional Activities (EPAs) In Hematology/Oncology (HO) Training Programs -- A Proactive And Practical Approach to a New Evaluation System.

    Accreditation Council of Graduate Medical Education, 2014

  • Use of an Attenuated Version of a Strongly Immunogenic, Peptide-based Vaccine to Enhance an Anti-cancer Immune Response against Folate Receptor-alpha (FR alpha)

    Annals Of Surgical Oncology, 2013

  • Abstract P4-13-05: HLA-A2 is not a prognostic indicator in breast cancer: Implications for cancer vaccine trials

    Cancer Research, 2013

  • Use of an attenuated version of a strongly immunogenic, peptide-based vaccine to enhance an anti-cancer immune response against folate receptor-alpha.

    Cancer Research, 2013

  • Breast cancer patients with HER2 low-expression: An under-recognized group at significant risk for recurrence

    Cancer Research, 2013

  • Preliminary results for the phase 1 trial of a dual HER2 peptide cancer vaccine in breast and ovarian cancer patients

    Cancer Research, 2013

  • Safety and efficacy of the HER2-derived GP2 peptide vaccine in combination with trastuzumab for breast cancer patients in the adjuvant setting.

    ASCO Annual Meeting Proceedings, 2013

  • Risk factors for development of delayed urticarial reactions in the phase II trial of HER2 peptide vaccines plus GM-CSF versus GM-CSF alone in high-risk breast cancer patients to prevent recurrence.

    ASCO Annual Meeting Proceedings, 2013

  • Vaccine-specific T-cell proliferation in response to a dual peptide cancer vaccine in breast and ovarian cancer patients.

    Journal for Immunotherapy of Cancer, 2013

  • Prospective survey study regarding the implementation of new communication skills curriculum for medical oncology trainees.

    ASCO Annual Meeting Proceedings, 2012

  • An assessment of disease features and immune response in breast cancer patients that did not recur after receiving HER2 peptide, AE37 vaccine in a randomized phase II trial.

    ASCO Annual Meeting Proceedings, 2012

  • Early efficacy analysis of the AE37 vaccine in patients with HER2 low-expressing and triple-negative breast cancer.

    ASCO Annual Meeting Proceedings, 2012

  • Safety and long-term maintenance of anti-HER2 immunity following booster inoculations of the E75 breast cancer vaccine.

    ASCO Annual Meeting Proceedings, 2012

  • Cancer vaccines: should we be targeting patients with less aggressive disease?

    Expert Review of Vaccines, 2012

  • Trends in Circulating Tumor Cells (CTCS) in Multiple Adjuvant (ADJ) Trials of HER2-Specific Peptide Vaccines (PV) in Breast Cancer (BRCA) PTS

    Journal of Immunotherapy, 2012

  • From bench to bedside: The use of the li-Key technology to improve helper peptides for clinical use in cancer vaccines.

    ASCO Annual Meeting Proceedings, 2012

  • The combination of trastuzumab and HER2-directed peptide vaccines is safe in HER2-expressing breast cancer patients

    Cancer Research, 2012

  • Abstract LB-218: Immune response assessment in a phase II trial of AE37 HER2 peptide vaccine

    American Association for Cancer Research AACR, 2012

  • Immune reconstitution after chemotherapy correlates with increased in vitro immune response in breast cancer patients undergoing peptide vaccine therapy

    Cancer Research, 2012

  • Abstract LB-218: Immune response assessment in a phase II trial of AE37 HER2 peptide vaccine

    Cancer Research, 2012

  • Abstract P2-11-01: Final pre-specified analysis of the phase II trial of the GP2+ GM-CSF peptide vaccine in high risk breast cancer patients to prevent recurrence

    Cancer Research, 2012

  • Sequential administration of trastuzumab and a CD8 T-cell-eliciting HER2/neu peptide vaccine in patients with breast cancer compared to trastuzumab alone.

    ASCO Annual Meeting Proceedings, 2011

  • Monitoring of circulating tumor cell trends in a prospective, randomized, placebo-controlled HER2/neu peptide vaccine trial.

    ASCO Annual Meeting Proceedings, 2011

  • AE37: a novel T-cell-eliciting vaccine for breast cancer

    Expert Opinion on Biological Therapy, 2011

  • Advances in the Management of Triple Negative Breast Cancer Ch.9: Targeted therapies: other agents in clinical trials

    Advances in the Management of Triple Negative Breast Cancer, 2011

  • Therapeutic Breast Cancer Vaccines

    BioDrugs, 2009

  • A randomized pilot study comparing aprepitant to olanzapine for treatment of chemotherapy-induced nausea and vomiting

    ASCO Annual Meeting Proceedings, 2009

  • Optical density values correlate with the clinical probability of heparin induced thrombocytopenia

    Journal of Thrombosis and Thrombolysis, 2008

  • Presence and treatment of air hunger in severely ill patients

    Respiratory Medicine, 2008

  • Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis

    Archives of Internal Medicine, 2006

  • Hematology Consultation along with the 4 T’s Clinical Scoring System Improves the Evaluation and Management of Heparin Induced Thrombocytopenia.

    Blood, 2004

  • Treating Air Hunger at End-of-Life

    CHEST Journal, 2004

  • Prospective Observation of Air Hunger in Severely Ill Patients

    CHEST Journal, 2004

  • Treatment of air hunger at end of life

    American Thoracic Society ATS, 2002